RENACTIF: Reduction of the Thrombotic Phenotype in Renal Insufficiency With N-AcetylCysteine
RENACTIF: Reduction of the Thrombotic Phenotype in Renal Insufficiency With N-AcetylCysteine A Randomized, Double-blind, Placebo-controlled, Cross-over Trial
Sponsor: Assistance Publique Hopitaux De Marseille
Listed as NCT03636932, this PHASE2 trial focuses on Chronic Kidney Diseases and remains completed. Sponsored by Assistance Publique Hopitaux De Marseille, it has been updated 7 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Oct 2021 — Jun 2023 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Jun 2019 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2018 — Jun 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Assistance Publique Hopitaux De Marseille
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Marseille, France